Pharming (PHAR) EBIAT (2020 - 2025)
Historic EBIAT for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $22.4 million.
- Pharming's EBIAT rose 226982.59% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 6340.73%. This contributed to the annual value of -$11.8 million for FY2024, which is 1225.82% down from last year.
- Per Pharming's latest filing, its EBIAT stood at $22.4 million for Q3 2025, which was up 226982.59% from -$10.3 million recorded in Q2 2025.
- Pharming's 5-year EBIAT high stood at $22.4 million for Q3 2025, and its period low was -$14.9 million during Q1 2025.
- For the 5-year period, Pharming's EBIAT averaged around -$2.4 million, with its median value being -$5.7 million (2024).
- Per our database at Business Quant, Pharming's EBIAT skyrocketed by 4966972.53% in 2022 and then tumbled by 16935.67% in 2023.
- Pharming's EBIAT (Quarter) stood at -$13.3 million in 2021, then dropped by 9.89% to -$14.6 million in 2022, then rose by 27.75% to -$10.5 million in 2023, then dropped by 4.32% to -$11.0 million in 2024, then skyrocketed by 303.89% to $22.4 million in 2025.
- Its last three reported values are $22.4 million in Q3 2025, -$10.3 million for Q2 2025, and -$14.9 million during Q1 2025.